
Releases
MindMaze Therapeutics Streamlines Operations and Secures Funding
MindMaze Therapeutics has finalized an organizational restructuring and secured an initial CHF 4 million infusion as part of an CHF 8 million equity deal with Neuro.io Group SA. The moves aim to anchor the Geneva-based firm’s focus on its core neurology business while sharpening its U.S. commercial strategy.






















